• Vaccine Name: Melanoma DNA vaccine VR-S8/VR-IL2/AD-S8 encoding survivin
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0004432
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• Survivin gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector VR expressed novel truncations of survivin, is overexpressed in major types of cancer and is considered an ideal ‘‘universal’’ tumor-associated antigen (Zhang et al., 2012).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000334
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccine Immune Response Type: VO_0000286
• Efficacy: Tumors were significantly inhibited in mice boosted with AD-S8 compared with those in mice given VR-S8/VR- IL2 (P < 0.01). Moreover, complete tumor rejection occurred in 5 of 15 mice, while no tumor rejection was observed in the control group. A Kaplan–Meier plot showed that 53.3% of the mice in the AD-S8- boosted group were alive at 50 days with survival prolonged by 35.6%, whereas only 6.7% of the mice in the VR-S8/VR-IL2 and VR-S8 groups were alive with survival prolonged by 17 and 10.5%, respectively (Zhang et al., 2012).